doi: 10.1007/s12094-009-0379-x.
Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question
- PMID: 19574198
- DOI: 10.1007/s12094-009-0379-x
Item in Clipboard
Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question
Clin Transl Oncol.
2009 Jul.
No abstract available
Similar articles
-
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.J Neurooncol. 2016 Feb;126(3):425-31. doi: 10.1007/s11060-015-1996-6. Epub 2015 Nov 24. J Neurooncol. 2016. PMID: 26603162
-
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.J Clin Pharm Ther. 2010 Dec;35(6):657-63. doi: 10.1111/j.1365-2710.2009.01148.x. J Clin Pharm Ther. 2010. PMID: 21054456 Review.
-
Aprepitant--a novel NK1-receptor antagonist.Expert Opin Pharmacother. 2003 Dec;4(12):2279-96. doi: 10.1517/14656566.4.12.2279. Expert Opin Pharmacother. 2003. PMID: 14640927 Review.
-
Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.Cancer Chemother Pharmacol. 2014 Jun;73(6):1129-36. doi: 10.1007/s00280-014-2446-4. Epub 2014 Apr 21. Cancer Chemother Pharmacol. 2014. PMID: 24748417 Clinical Trial.
-
[Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].Bull Cancer. 2009 Feb;96(2):141-5. doi: 10.1684/bdc.2008.0819. Bull Cancer. 2009. PMID: 19258220 French.
Cited by
-
Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.Neuro Oncol. 2019 Jan 1;21(1):47-58. doi: 10.1093/neuonc/noy123. Neuro Oncol. 2019. PMID: 30085274 Free PMC article.
-
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.Oncotarget. 2013 Apr;4(4):502-30. doi: 10.18632/oncotarget.969. Oncotarget. 2013. PMID: 23594434 Free PMC article. Review.
-
Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines.Br J Pharmacol. 2010 Oct;161(3):481-7. doi: 10.1111/j.1476-5381.2010.00923.x. Br J Pharmacol. 2010. PMID: 20880389 Free PMC article. Review.
-
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.J Neurooncol. 2016 Feb;126(3):425-31. doi: 10.1007/s11060-015-1996-6. Epub 2015 Nov 24. J Neurooncol. 2016. PMID: 26603162
-
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Oncotarget. 2014 Sep 30;5(18):8052-82. doi: 10.18632/oncotarget.2408. Oncotarget. 2014. PMID: 25211298 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical